T he treatment of coronary artery disease patients with revascularization procedures has escalated dramatically in the 1980s. In 1989, an estimated 450,000 coronary artery revascularization procedures were performed with either percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG); in 1980, less than 250,000 such procedures were performed. Despite the dramatic increase in the use of coronary revascularization procedures, the relative efficacy of PTCA and CABG in the treatment of coronary artery disease patients remains poorly understood. In the last 3 years, a number of comparative randomized prospective trials evaluating the relative efficacy of PTCA and CABG have been planned and initiated. In the United States, the National Heart, Lung, and Blood Institute (NHLBI) is sponsoring two such comparative trials: the Emory Angioplasty Surgery Trial (EAST) and the Bypass Angioplasty Revascularization Investigation (BARI). Three similar trials are underway in Western Europe.
Because coronary revascularization is based on the angiographic assessment of coronary lesion severity, investigators in trials comparing PTCA and CABG have had to implement objective and reproducible methodologies for assessing coronary artery lesion severity. If one is to assess the ischemia-producing potential of a particular coronary lesion, direct measurement of impairment of coronary flow and reduction in coronary flow reserve is the reference standard against which angiographic measurements must be compared.' To a variable extent, the percent coronary diameter stenosis,' minimum residual lumen diameter,2 minimum lesion cross-sectional area,3 and the flow resistance (computed from the full-lesion geometric profile)4 all correlate with measures of resting flow and coronary flow reserve. Historically, clinical assessment of coronary artery lesion severity has relied on visual determination of the percent diameter stenosis. This measurement intuitively re-flects the severity of luminal obstruction, and it is simply assessed. In the 1970s, however, a number of different investigations documented the large amount of interobserver variability and the poor reproducibility of visual assessments of coronary artery lesion percent diameter stenosis.5-8 Despite this well-documented lack of objectivity, clinical practice today continues to rely on visual assessment for the description of lesion severity. Indeed, studies that use visual assessment to describe lesion severity continue to be published in leading cardiology journals despite the well-documented problems with poor reproducibility and lack of accuracy of this methodology.
A requirement for objectivity is inherent in the design of any multicenter, randomized, prospective study in which angiography is an integral part. Thus, investigators participating in trials comparing coronary revascularization strategies have had to implement methods for assessing coronary lesion severity that are more objective than the current clinically accepted standard of visual assessment. The purposes of this editorial are to review methodologies for assessment of coronary lesion severity, to explore the consequences of a shift to more objective methods of lesion assessment relative to the current clinical standard of visual assessment, and to propose definitions that will enhance the goal of achieving a more objective and reproducible assessment of coronary lesion severity.
Computer however, may be present. TIMI flow is always graded zero for such lesions. Thus, it is possible to construct a continuum of measures of lesion severity that is reproducible using a combination of objective methodology and morphological definitions. For lesions greater than 0% diameter stenosis and less than 85-90% diameter stenosis, caliper or computer-assisted methodology provides reproducible measurement of lesion severity. For lesions greater than 85-90% diameter stenosis, arbitrary morphological definitions allow reproducible categorization of lesion severity. When one initiates objective measurements of coronary lesion severity, whether by ruler, caliper, or computer quantification, there is often substantial lessening of lesion severity compared with prior visual estimates. It is, however, important that individual angiographers, angioplasters, and surgeons accommodate a resetting of their lesion severity thresholds if angiographic interpretation is to be recognized as an accurate and credible laboratory procedure. Objective measurements avoid the impression of biased interpretation of diagnostic test results; this is especially important when the same individuals perform diagnostic studies, interpret them and then act on the results of the interpretation by performing PTCA. In addition, continued use of visual estimates of lesion severity before and after angioplasty may be fostering unrealistic impressions about the extent of lesion reduction that is accomplished. Moreover, the lack of reproducibility of visual estimates makes it difficult to interpret clinical investigative studies. If one is to compare results of clinical research studies that evaluate such topics as angioplasty outcomes, prognosis of coronary disease subsets, or atheroma progression and regression, standardization and objective assessment of coronary lesion severity is necessary. Investigators in the NHLBI sponsored trials of coronary revascularization (EAST and BARI) have adopted objective methodologies for describing lesion severity. It is quite probable that these methodologies will lead to assessments of lesion severity in these trials that are "less severe" than many clinical cardiologists would accept as being clinically severe.18 Indeed, it is quite probable that the average lesion severity reported from these trials of revascularization treatment strategies will be in the 70% diameter stenosis range and not in the 90% diameter stenosis range as is often the case when visual assessment methods are used. As this editorial has attempted to show, this type of disparity will not reflect an "easier" patient population being enrolled in BARI and EAST compared with current clinical practice; it simply will reflect the use of objective methodologies rather than biased visual assessments. Finally, the clinical cardiovascular community must realize that appropriate integration of angiographic observations from trials such as BARI and EAST in routine clinical practice will require adoption of objective assessment methodologies for description of coronary lesion severity in everyday practice.
There are limitations of objective techniques for assessing lesion severity. For It must be recognized that current visual estimates of lesion percent diameter stenosis severity are often biased in the direction of heightening the degree of luminal impairment. This biasing often occurs with the honest goal of identifying patients who would benefit from revascularization; however, it is critical for the credibility and integrity of clinical decision making that biases underlying the current practice of visual estimation of lesion severity be acknowledged and corrected. We believe that the community of cardiovascular specialists can accommodate an adjustment in their perceptions and attitudes toward thresholds of lesion severity in recognition of the importance of obtaining objective and reproducible reporting of coronary lesion severity. Implementation of objective measurement techniques for assessing angiographically defined lesion severity by the clinical cardiology community is an important -and overdue -practice that will improve the reliability of angiographic findings and that will lead to improved credibility in the selection of patients for coronary revascularization.
